468.41
price up icon1.64%   7.58
after-market Handel nachbörslich: 468.41
loading
Schlusskurs vom Vortag:
$460.83
Offen:
$464.33
24-Stunden-Volumen:
1.15M
Relative Volume:
0.76
Marktkapitalisierung:
$120.29B
Einnahmen:
$11.10B
Nettoeinkommen (Verlust:
$-988.90M
KGV:
-119.49
EPS:
-3.92
Netto-Cashflow:
$-1.26B
1W Leistung:
-0.37%
1M Leistung:
+6.14%
6M Leistung:
+6.09%
1J Leistung:
-5.97%
1-Tages-Spanne:
Value
$460.55
$468.98
1-Wochen-Bereich:
Value
$460.55
$480.00
52-Wochen-Spanne:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Firmenname
Vertex Pharmaceuticals Inc
Name
Telefon
(617) 341-6393
Name
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Name
Mitarbeiter
6,100
Name
Twitter
@VertexPharma
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
VRTX's Discussions on Twitter

Vergleichen Sie VRTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-07 Herabstufung Wolfe Research Outperform → Peer Perform
2025-05-06 Herabstufung Leerink Partners Outperform → Market Perform
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-02-12 Hochstufung Canaccord Genuity Sell → Hold
2025-02-11 Hochstufung Canaccord Genuity Sell → Hold
2025-01-30 Herabstufung Wells Fargo Overweight → Equal Weight
2024-12-20 Bestätigt H.C. Wainwright Buy
2024-12-19 Herabstufung Oppenheimer Outperform → Perform
2024-12-09 Hochstufung Jefferies Hold → Buy
2024-11-14 Eingeleitet Citigroup Buy
2024-10-16 Eingeleitet Scotiabank Sector Perform
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-08-05 Herabstufung Barclays Overweight → Equal Weight
2024-06-27 Eingeleitet Redburn Atlantic Buy
2024-04-11 Hochstufung Evercore ISI In-line → Outperform
2024-02-15 Eingeleitet Wolfe Research Outperform
2024-02-06 Herabstufung Evercore ISI Outperform → In-line
2024-02-02 Herabstufung Bernstein Outperform → Mkt Perform
2024-01-31 Herabstufung Maxim Group Buy → Hold
2024-01-31 Herabstufung Robert W. Baird Neutral → Underperform
2024-01-24 Herabstufung Canaccord Genuity Hold → Sell
2023-12-14 Bestätigt RBC Capital Mkts Sector Perform
2023-05-30 Eingeleitet William Blair Outperform
2023-05-04 Fortgesetzt Piper Sandler Overweight
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Hold
2023-01-17 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-12-19 Herabstufung Jefferies Buy → Hold
2022-07-13 Eingeleitet Cantor Fitzgerald Overweight
2022-06-01 Hochstufung Maxim Group Hold → Buy
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-05-06 Herabstufung Robert W. Baird Outperform → Neutral
2022-05-03 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-02-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Bestätigt JP Morgan Overweight
2022-01-27 Bestätigt Morgan Stanley Underweight
2022-01-27 Bestätigt RBC Capital Mkts Outperform
2022-01-27 Bestätigt Stifel Hold
2022-01-27 Bestätigt Wolfe Research Outperform
2022-01-20 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-12-09 Eingeleitet Wells Fargo Overweight
2021-11-19 Eingeleitet BMO Capital Markets Market Perform
2021-11-19 Herabstufung Piper Sandler Overweight → Neutral
2021-09-09 Herabstufung Stifel Buy → Hold
2021-09-07 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-07-20 Herabstufung SVB Leerink Mkt Perform → Underperform
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-07-01 Eingeleitet Raymond James Mkt Perform
2021-06-11 Herabstufung Daiwa Securities Outperform → Neutral
2021-02-23 Hochstufung Robert W. Baird Neutral → Outperform
2021-02-02 Bestätigt H.C. Wainwright Buy
2020-12-30 Eingeleitet Daiwa Securities Outperform
2020-11-30 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Eingeleitet Bernstein Outperform
2020-10-28 Eingeleitet UBS Buy
2020-07-31 Bestätigt H.C. Wainwright Buy
2020-07-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-04-30 Bestätigt H.C. Wainwright Buy
2020-04-28 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Eingeleitet Barclays Overweight
2020-01-31 Herabstufung Robert W. Baird Outperform → Neutral
2019-11-19 Hochstufung Guggenheim Neutral → Buy
2019-11-12 Eingeleitet SunTrust Buy
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-09-03 Hochstufung Goldman Neutral → Buy
2019-08-01 Herabstufung Needham Buy → Hold
2019-05-23 Fortgesetzt Citigroup Buy
2019-05-21 Eingeleitet Credit Suisse Outperform
2019-04-12 Eingeleitet Evercore ISI In-line
2019-03-26 Hochstufung William Blair Mkt Perform → Outperform
2019-03-19 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-02-06 Herabstufung Maxim Group Buy → Hold
Alle ansehen

Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten

pulisher
Jul 29, 2025

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Jul 29, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals' (VRTX) Upcoming Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential Amid Pipeline Advancements and Financial Resilience - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyMaximize your gains with expert trading tips - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What institutional investors are buying Vertex Pharmaceuticals Incorporated stockAI Powered Entry Points That Work - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN

Jul 28, 2025
pulisher
Jul 28, 2025

The 3 Things That Matter for Vertex Pharmaceuticals Now - AOL.com

Jul 28, 2025
pulisher
Jul 28, 2025

The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool

Jul 28, 2025
pulisher
Jul 28, 2025

Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance

Jul 28, 2025
pulisher
Jul 27, 2025

Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Rapid growth opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-27 22:21:17 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar

Jul 24, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail

Jul 23, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025

Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$558.14
price down icon 0.09%
$330.55
price up icon 1.77%
$598.79
price up icon 0.60%
biotechnology ONC
$305.74
price up icon 3.81%
$111.48
price down icon 1.16%
Kapitalisierung:     |  Volumen (24h):